Scene 1 (0s)
A Targeted Oncology Biotech
Scene 2 (12s)
▪ High-value, Difficult to Drug, Precision Oncology Targets DDR/ Synthetic Lethal programs Oncogenes ▪ Business Model: Licensing pre-clinical stage programs, and Partnering of earlier stage programs as Integrated Discovery collaborations Select list of programs selected and led to clinic
Scene 3 (37s)
Srikant Viswanadha, Founder & CEO CSO Murthy Chavali (CSN), Founder & CEO Sukanya Patra, Director, Biology Navnath P. Karche, Director Chemistry John Bondo Hansen, Formerly VP MedChem, Novo Nordisk Ali Fattaey CEO, Metabomed Debasish Roychowdhary, Formerly Sr VP Oncology, Sanofi Sundeep Agrawal, Partner, Colt Ventures Management team Advisory board.
Scene 4 (1m 36s)
RAD51 highlights RAD51 represents a first-in-class opportunity in the DDR space Satya's compound focuses on a unique MoA, leading to higher cellular activity compared to other DDR targets, but with potentially lower safety concerns SOS1 highlights Satya's best in class compound has better PD compared to competitors, resulting in better efficacy Clinically, positioned for EGFR & RAS (both WT and mut) driven solid tumors Cancers Incidence in US* Addressable patient population Breast 290,560 46,495 Ovarian 1,15,130 23,026 Prostate 2,68,490 52,356 Pancreatic 62,210 10,887 NSCLC 1,98,862 35,795 Targeted patient population for RAD51i Targeted patient population for SOS1i Cancers Incidence in US* Addressable patient population NSCLC 1,98,862 39,772 CRC 1,51,030 27,185 HCC 30,945 4,178 Pancreatic 62,210 9,332 Prostate 2,68,490 42,958.
Scene 5 (3m 50s)
Thank You murthycsn@satyarx.com.